GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (FRA:GXE) » Definitions » Cyclically Adjusted PB Ratio

Galapagos NV (FRA:GXE) Cyclically Adjusted PB Ratio : 0.65 (As of Jun. 26, 2025)


View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV Cyclically Adjusted PB Ratio?

As of today (2025-06-26), Galapagos NV's current share price is €23.66. Galapagos NV's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €36.36. Galapagos NV's Cyclically Adjusted PB Ratio for today is 0.65.

The historical rank and industry rank for Galapagos NV's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:GXE' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.58   Med: 1.49   Max: 11.89
Current: 0.65

During the past years, Galapagos NV's highest Cyclically Adjusted PB Ratio was 11.89. The lowest was 0.58. And the median was 1.49.

FRA:GXE's Cyclically Adjusted PB Ratio is ranked better than
68.57% of 684 companies
in the Biotechnology industry
Industry Median: 1.49 vs FRA:GXE: 0.65

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Galapagos NV's adjusted book value per share data for the three months ended in Mar. 2025 was €41.700. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €36.36 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Galapagos NV Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Galapagos NV's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Cyclically Adjusted PB Ratio Chart

Galapagos NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.75 2.26 1.49 1.16 0.74

Galapagos NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 0.68 0.75 0.74 0.63

Competitive Comparison of Galapagos NV's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Galapagos NV's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Cyclically Adjusted PB Ratio falls into.


;
;

Galapagos NV Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Galapagos NV's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=23.66/36.36
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galapagos NV's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Galapagos NV's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=41.7/134.3475*134.3475
=41.700

Current CPI (Mar. 2025) = 134.3475.

Galapagos NV Quarterly Data

Book Value per Share CPI Adj_Book
201506 11.401 100.107 15.301
201509 10.735 100.245 14.387
201512 9.341 100.572 12.478
201603 15.894 101.653 21.006
201606 15.827 102.267 20.792
201609 15.324 102.118 20.160
201612 16.402 102.614 21.474
201703 16.174 103.972 20.899
201706 21.016 103.902 27.174
201709 0.000 104.170 0.000
201712 19.867 104.804 25.467
201803 17.553 105.419 22.370
201806 17.252 106.063 21.853
201809 21.883 106.618 27.574
201812 22.294 107.252 27.926
201903 21.528 107.876 26.811
201906 20.856 107.896 25.969
201909 40.922 107.470 51.156
201912 44.469 108.065 55.284
202003 43.815 108.550 54.228
202006 42.499 108.540 52.604
202009 41.507 108.441 51.423
202012 40.824 108.511 50.544
202103 41.236 109.522 50.583
202106 40.649 110.305 49.509
202109 39.942 111.543 48.108
202112 40.324 114.705 47.229
202203 40.315 118.620 45.660
202206 40.270 120.948 44.731
202209 40.864 124.120 44.231
202212 38.368 126.578 40.723
202303 38.918 126.528 41.323
202306 39.212 125.973 41.819
202309 39.783 127.083 42.057
202312 42.423 128.292 44.425
202403 43.932 130.552 45.209
202406 44.164 130.691 45.400
202409 43.440 130.968 44.561
202412 43.962 132.346 44.627
202503 41.700 134.348 41.700

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Galapagos NV  (FRA:GXE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Galapagos NV Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV Business Description

Industry
Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Galapagos NV Headlines

No Headlines